Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 8
Submit an article Journal homepage
1,181
Views
1
CrossRef citations to date
0
Altmetric
Hematology

Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study

Marianne Chacón-Arayaa Roche Central America & Caribbean, Heredia, Costa Rica; Correspondence[email protected]
,
Diego Rey-Rodríguezb Department of Nephrology, Hospital Santo Tomás, Panama, Panama;
,
Felipe Rodríguez De Leónc Caja de Seguro Social, Complejo Hospitalario Dr. Arnulfo Arias Madrid, Panama, Panama;
,
Allan Ramos-Esquiveld Department of Pharmacology School of Medicine, University of Costa Rica, San José, Costa Rica;
&
Tao Sunninge United BioSource Corporation, Montreal, Canada
Pages 736-741 | Received 03 Dec 2018, Accepted 20 Mar 2019, Published online: 12 Apr 2019

References

  • Jha V, Garcia-Garcia G, Iseki K. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–267.
  • Tonelli M, Riella M. Chronic kidney disease and the aging population. Am J Nephrol. 2014;39:248–251.
  • Fresenius Medical Care. ESRD patients in 2013: a global perspective. Bad Homburg, Germany: Fresenius Medical Care AG & Co. KGaA; 2014.
  • Moreno-Velásquez I, Castro F, Gómez B, et al. Chronic kidney disease in Panama: results from the PREFREC study and national mortality trends. Kidney Int Rep. 2017;2:1032–1041.
  • KDOQI. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–S145.
  • De Cock E, Dellanna F, Khellaf K, et al. Time savings associated with CERA once monthly: a time-and-motion study in hemodialysis centers in five European countries. J Med Econ. 2013;16:648–656.
  • Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25:4009–4017.
  • Mann JF, de Francisco A, Nassar G, et al. Fewer dose changes with once-monthly CERA in patients with chronic kidney disease. Clin Nephrol. 2011;76:9–15.
  • Cases A, Portolés J, Calls J, et al. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to CERA in CKD patients in clinical practice: MINERVA study. Int Urol Nephrol. 2014;46:1983–1995.
  • Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous CERA: the MIRACEL study. Curr Med Res Opin. 2010;26:1083–1089.
  • Maoujoud O, Ahid S, Dkhissi H, et al. The cost-effectiveness of continuous erythropoiesis receptor activator once monthly versus epoetin thrice weekly for anaemia management in chronic haemodialysis patients. Anemia. 2015;2015:189404.
  • Gonzalez P, Gomez E, Vargas J. PSY25 renal anemia (RA) treatment in Mexican public health care institutions: an evaluation of the costs and consequences. Value Health. 2009;12:A379–A380.
  • Maoujoud O, Ahid S, Cherrah Y. The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. Int J Nephrol Renovasc Dis. 2016;9:35–43.
  • Barnes RM. Motion and time study: design and measurement of work, 7th edn. Wiley; 1980. ISBN: 978-0-471-05905-9
  • Mikhail A, Brown C, Williams JA. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18:345.
  • Government of Panama. La Gaceta Oficial. 2015. [cited 2018 Oct 2]. Available from: https://www.gacetaoficial.gob.pa/pdfTemp/27921/GacetaNo_27921_20151203.pdf
  • Instituto Nacional de Estadística y Censo. Contraloría General de la República de Panamá. 2016. [cited 2018 Oct 9]. Available from: https://www.contraloria.gob.pa/inec/Publicaciones/Publicaciones.aspx?ID_SUBCATEGORIA=37&ID_PUBLICACION=831&ID_IDIOMA=1&ID_CATEGORIA=5
  • Schiller B, Doss S, De Cock E, et al. Costs of managing anemia with erythropoiesis stimulating agents during hemodialysis: a time and motion study. Hemodial Int. 2008;12:441–449.
  • Chan KE, Thadhani RI, Maddux FW. Adherence barriers to chronic dialysis in the United States. J Am Soc Nephrol. 2014;25:2642–2648.
  • Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646.
  • Parsons H. What happened at Hawthorne? New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies Science. 1974;183:922–932.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.